Neurocrine Biosciences, Inc. presented data from over 300 patients diagnosed with tardive dyskinesia (TD) and treated with INGREZZA capsules. These data showed significant improvements in functional, social, emotional, and health-related quality of life measures in Phase 3 and 4 studies.
Real-world practice data also demonstrated improvements in functional, social, independence, emotional, and physical aspects of patients' lives, as well as antipsychotic adherence. The Tardive Dyskinesia Impact Scale (TDIS) scores consistently improved across all items, indicating benefits in both physical and socio-emotional domains.
In a Phase 4 study, health-related quality of life (HRQOL) measured by EQ-5D-5L showed significant improvements at Week 16, with scores returning to or near baseline after a four-week washout period. This comprehensive data set reinforces INGREZZA's value in treating the multifaceted impact of TD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.